Immunotherapy in Metastatic Malignant Melanoma and Non-Small Cell Lung Cancer; a Brief Review and Position Statement from the Immuno-Oncology Clinical Forum (IOCF), Iran

Document Type: Brief Report

Authors

1 NK Basile Cancer Institute, American University of Beirut Medical Center, Beirut

2 Department of Hematology-Oncology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran

3 Behphar Scientific Committee, Behphar Group, Tehran, Iran

4 Hematology-Oncology Division, Atieh Hospital, Tehran, Iran

5 Department of Hematology-Oncology, School of Medicine, Babol University of Medical Sciences, Babol, Iran

6 Department of Hematology-Oncology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

7 Department of Neuroscience, School of Advanced Medical Sciences and Technologies, Shiraz University of Medical Sciences, Shiraz, Iran

Abstract

Given the unmet needs in cancer treatment, extensive research and development has evolved to offer therapies for cancers to extend survival and minimize side effects. Immunotherapy, an approach to harness normal immune cells against cancers not only today’s breakthrough but in fact the future of oncology therapeutics. Taking into consideration the recent approvals for new lines of therapy including anti-programmed-death-1 or programmed-death-1 ligand (PD-1/PD-L1) monoclonal antibodies for the treatment of Malignant Melanoma (MM) and Non-Small Cell Lung Cancer (NSCLC), local strategies need to be established following the field experts’ concurrence. Expert input forums are among the key approaches to define locally-adapted clinical-pathways with regard to the novel treatments. To this end, a panel of Iranian medical oncology experts reviewed the available evidence, taking into consideration recent practice guidelines with regard to the treatment of MM and NSCLC in order to draw an agreed-upon approach highlighting the position of immunotherapy in their current practice. Having addressed the key questions and considering the possible limitations and challenges, the panel could reach an agreed position. This report highlights the discussions with regards to the role of immunotherapy in MM and NSCLC during the immune-oncology clinical forum (IOCF) comprising an Iranian panel of experts.

Keywords


  1. Flati V, Corsetti G, Pasini E, Rufo A, Romano C, Dioguardi FS. Nutrition, Nitrogen Requirements, Exercise and Chemotherapy-Induced Toxicity in Cancer Patients. A puzzle of Contrasting Truths? Anti-cancer agents in medicinal chemistry. 2015;16(1):89-100.
  2. Luciani A, Biganzoli L, Colloca G, Falci C, Castagneto B, Floriani I, et al. Estimating the risk of chemotherapy toxicity in older patients with cancer: The role of the Vulnerable Elders Survey-13 (VES-13). Journal of geriatric oncology. 2015;6(4):272-279.
  3. Sgambato A, Casaluce F, Sacco PC, Palazzolo G, Maione P, Rossi A, et al. Anti PD-1 and PDL-1 immunotherapy in the treatment of advanced non-small cell lung cancer (NSCLC): a review on toxicity profile and its management. Current drug safety. 2015.
  4. Yang Y. Cancer immunotherapy: harnessing the immune system to battle cancer. The Journal of clinical investigation. 2015;125(9):3335-3337.
  5. Zheng P, Zhou Z. Human Cancer Immunotherapy with PD-1/PD-L1 Blockade. Biomarkers in cancer. 2015;7(Suppl 2):15-18.
  6. Sullivan RJ, Flaherty KT. Immunotherapy: Anti-PD-1 therapies-a new first-line option in advanced melanoma. Nature reviews Clinical oncology. 2015;12(11):625-626.
  7. Kroemer G, Galluzzi L. Immunotherapy of hematological cancers: PD-1 blockade for the treatment of Hodgkin's lymphoma. Oncoimmunology. 2015;4(6):e1008853.
  8. Luke JJ, Ott PA. PD-1 pathway inhibitors: the next generation of immunotherapy for advanced melanoma. Oncotarget. 2015;6(6):3479-3492.
  9. Muenst S, Soysal SD, Tzankov A, Hoeller S. The PD-1/PD-L1 pathway: biological background and clinical relevance of an emerging treatment target in immunotherapy. Expert opinion on therapeutic targets. 2015;19(2):201-211.
  10. Noorbala MT, Mohammadi S, Noorbala M. Cutaneous malignant melanoma in central iran: a 20-year study. Iranian Red Crescent medical journal. 2013;15(8):690-694.
  11. Noormohammadpour P, Ehsani A, Mirshams Shashahani M, Shahmohammadi F, Gholamali F. [Demographic and clinical characteristics of patients with malignant melanoma attending a referral skin tumors clinic in Iran: A 5-year study] (In Persian). Dermatology and Cosmetics. 2014;5(1):9-15.
  12. Sandru A, Voinea S, Panaitescu E, Blidaru A. Survival rates of patients with metastatic malignant melanoma. Journal of medicine and life. 2014;7(4):572-576.
  13. Meng XJ, Ao HF, Huang WT, Chen F, Sun XC, Wang JJ, et al. Impact of different surgical and postoperative adjuvant treatment modalities on survival of sinonasal malignant melanoma. BMC cancer. 2014;14:608.
  14. Eriksson H, Lyth J, Mansson-Brahme E, Frohm-Nilsson M, Ingvar C, Lindholm C, et al. Later stage at diagnosis and worse survival in cutaneous malignant melanoma among men living alone: a nationwide population-based study from Sweden. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2014;32(13):1356-1364.
  15. Plym A, Ullenhag GJ, Breivald M, Lambe M, Berglund A. Clinical characteristics, management and survival in young adults diagnosed with malignant melanoma: A population-based cohort study. Acta oncologica. 2014;53(5):688-696.
  16. Patel F, Wilken R, Burrall B, Martinez S, Wells V, King B, et al. Detailed protocol for administration of intralesional IL-2 for the treatment of Stage IIIc and IV M1a metastatic melanoma based on current NCCN guidelines. Dermatology online journal. 2014;20(11).
  17. Coit DG, Andtbacka R, Anker CJ, Bichakjian CK, Carson WE, 3rd, Daud A, et al. Melanoma, version 2.2013: featured updates to the NCCN guidelines. Journal of the National Comprehensive Cancer Network : JNCCN. 2013;11(4):395-407.
  18. Pembrolizumab PI 2015. Available from: https://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf, Retrieved on 28 November 2015.
  19. Nivolumab PI 2015. Available from: http://packageinserts.bms.com/pi/pi_opdivo.pdf, Retrieved on 28 November 2015.
  20. Barnhart C. Pembrolizumab: First in Class for Treatment of Metastatic Melanoma. Journal of the advanced practitioner in oncology. 2015;6(3):234-238.
  21. Marriott E, Praet C, Aguiar-Ibanez R, Pellissier J, Xu R, Wang J. Cost-Effectiveness of Pembrolizumab for Unresectable Metastatic Melanoma After Progression with Ipilimumab in England. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 2015;18(7):A453.
  22. Hua C, Boussemart L, Mateus C, Routier E, Boutros C, Cazenave H, et al. Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab. JAMA dermatology. 2015:1-7.
  23. Improta G, Leone I, Donia M, Gieri S, Pelosi G, Fraggetta F. New developments in the management of advanced melanoma - role of pembrolizumab. OncoTargets and therapy. 2015;8:2535-2543.
  24. Faghfuri E, Faramarzi MA, Nikfar S, Abdollahi M. Nivolumab and pembrolizumab as immune-modulating monoclonal antibodies targeting the PD-1 receptor to treat melanoma. Expert review of anticancer therapy. 2015;15(9):981-993.
  25. Kumar SS, McNeil CM. Pembrolizumab for the treatment of melanoma. Expert review of clinical pharmacology. 2015;8(5):515-527.
  26. Tan M, Quintal L. Pembrolizumab: a novel antiprogrammed death 1 (PD-1) monoclonal antibody for treatment of metastatic melanoma. Journal of clinical pharmacy and therapeutics. 2015.
  27. Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. The Lancet Oncology. 2015;16(8):908-918.
  28. Rajakulendran T, Adam DN. Spotlight on pembrolizumab in the treatment of advanced melanoma. Drug design, development and therapy. 2015;9:2883-2886.
  29. Sullivan RJ, Flaherty KT. Pembrolizumab for Treatment of Patients with Advanced or Unresectable Melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015;21(13):2892-2897.
  30. Martin-Liberal J, Kordbacheh T, Larkin J. Safety of pembrolizumab for the treatment of melanoma. Expert opinion on drug safety. 2015;14(6):957-964.
  31. Bohensky M, Pasupathi K, Gorelik A, Kim H, Harrison JP, Liew D. A Cost Effectiveness Analysis of Nivolumab Compared to Ipilimumab for the Treatment of Braf Wild-Type Advanced Melanoma in Australia. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 2015;18(7):A340.
  32. Tsai KK, Daud AI. Nivolumab plus ipilimumab in the treatment of advanced melanoma. Journal of hematology & oncology. 2015;8(1):123.
  33. Freeman-Keller M, Kim Y, Cronin H, Richards A, Gibney G, Weber J. Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015.
  34. Somasundaram R, Herlyn M. Nivolumab in combination with ipilimumab for the treatment of melanoma. Expert review of anticancer therapy. 2015;15(10):1135-1141.
  35. Mashima E, Inoue A, Sakuragi Y, Yamaguchi T, Sasaki N, Hara Y, et al. Nivolumab in the treatment of malignant melanoma: review of the literature. OncoTargets and therapy. 2015;8:2045-2051.
  36. Sadjadi A, Nouraie M, Mohagheghi MA, Mousavi-Jarrahi A, Malekezadeh R, Parkin DM. Cancer occurrence in Iran in 2002, an international perspective. Asian Pacific journal of cancer prevention : APJCP. 2005;6(3):359-363.
  37. Hosseini M, Seyed Alinaghi SA, Adimi Naghan P, Karimi S, Bahadori M, Khodadad K, et al. A Clinicopathologic Study of Lung Cancer Cases in Iran. Tanaffos. 2009;8(3):28-36.
  38. Pirker R. Adjuvant chemotherapy of non-small cell lung cancer. Tanaffos. 2012;11(1):12-17.
  39. Attarian H, Rezvani H, Ghadyani M, Eshaghi F. Consolidation chemotherapy with docetaxel after platinum-based chemotherapy in patients with non-small cell lung cancer: a preliminary report. Tanaffos. 2011;10(3):20-23.
  40. Mayor M, Yang N, Sterman D, Jones DR, Adusumilli PS. Immunotherapy for non-small cell lung cancer: current concepts and clinical trials. European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery. 2015.
  41. Daly ME, Monjazeb AM, Kelly K. Clinical Trials Integrating Immunotherapy and Radiation for Non-Small-Cell Lung Cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2015.
  42. Pennell NA. Understanding the Rationale for Immunotherapy in Non-Small Cell Lung Cancer. Seminars in oncology. 2015;42 Suppl 2:S3-S10.
  43. Socinski MA. Incorporating Immunotherapy Into the Treatment of Non-Small Cell Lung Cancer: Practical Guidance for the Clinic. Seminars in oncology. 2015;42 Suppl 2:S19-28.
  44. Garon EB. Current Perspectives in Immunotherapy for Non-Small Cell Lung Cancer. Seminars in oncology. 2015;42 Suppl 2:S11-18.
  45. Printz C. Immunotherapy drug improves survival of patients with squamous non-small cell lung cancer. Cancer. 2015;121(20):3562-3563.
  46. Rice SJ, Miller B, Wagman M, Jamorabo DS, Liu X, Belani CP. Clinical Approaches to Immunotherapy in Non-Small Cell Lung Cancer: Current and Future Perspectives. Current molecular pharmacology. 2015.
  47. Waqar SN, Morgensztern D. Immunotherapy for non-small cell lung cancer: are we on the cusp of a new era? Expert review of clinical immunology. 2015;11(8):871-873.
  48. Anagnostou VK, Brahmer JR. Cancer immunotherapy: a future paradigm shift in the treatment of non-small cell lung cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015;21(5):976-984.
  49. Socinski MA. Advances in Immuno-Oncology: Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer-Introduction. Seminars in oncology. 2015;42 Suppl 2:S1-2.
  50. Liu J, Yuan Y, Chen W, Putra J, Suriawinata AA, Schenk AD, et al. Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses. Proceedings of the National Academy of Sciences of the United States of America. 2015;112(21):6682-6687.
  51. Bedke J, Kruck S, Gakis G, Stenzl A, Goebell PJ. Checkpoint modulation--A new way to direct the immune system against renal cell carcinoma. Human vaccines & immunotherapeutics. 2015;11(5):1201-1208.
  52. Romano E, Romero P. The therapeutic promise of disrupting the PD-1/PD-L1 immune checkpoint in cancer: unleashing the CD8 T cell mediated anti-tumor activity results in significant, unprecedented clinical efficacy in various solid tumors. Journal for immunotherapy of cancer. 2015;3:15.
  53. Ray A, Das DS, Song Y, Richardson P, Munshi NC, Chauhan D, et al. Targeting PD1-PDL1 immune checkpoint in plasmacytoid dendritic cell interactions with T cells, natural killer cells and multiple myeloma cells. Leukemia. 2015;29(6):1441-1444.
  54. Langer CJ. Emerging immunotherapies in the treatment of non-small cell lung cancer (NSCLC): the role of immune checkpoint inhibitors. American journal of clinical oncology. 2015;38(4):422-430.
  55. Kakavand H, Vilain RE, Wilmott JS, Burke H, Yearley JH, Thompson JF, et al. Tumor PD-L1 expression, immune cell correlates and PD-1+ lymphocytes in sentinel lymph node melanoma metastases. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 2015.
  56. Ascierto PA, Marincola FM. 2015: The Year of Anti-PD-1/PD-L1s Against Melanoma and Beyond. EBioMedicine. 2015;2(2):92-93.
  57. Gangadhar TC, Salama AK. Clinical applications of PD-1-based therapy: a focus on pembrolizumab (MK-3475) in the management of melanoma and other tumor types. OncoTargets and therapy. 2015;8:929-937.
  58. Taube JM, Young GD, McMiller TL, Chen S, Salas JT, Pritchard TS, et al. Differential Expression of Immune-Regulatory Genes Associated with PD-L1 Display in Melanoma: Implications for PD-1 Pathway Blockade. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015;21(17):3969-3976.
  59. Mahoney KM, Freeman GJ, McDermott DF. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma. Clinical therapeutics. 2015;37(4):764-782.
  60. Curran MA, Montalvo W, Yagita H, Allison JP. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proceedings of the National Academy of Sciences of the United States of America. 2010;107(9):4275-4280.
  61. Ipilimumab PI 2015. Available from: http://packageinserts.bms.com/pi/pi_yervoy.pdf, Retrieved on 28 November 2015.
  62. Prodeus A, Abdul-Wahid A, Fischer NW, Huang EH, Cydzik M, Gariepy J. Targeting the PD-1/PD-L1 Immune Evasion Axis With DNA Aptamers as a Novel Therapeutic Strategy for the Treatment of Disseminated Cancers. Molecular therapy Nucleic acids. 2015;4:e237.
  63. Gatalica Z, Snyder C, Maney T, Ghazalpour A, Holterman DA, Xiao N, et al. Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2014;23(12):2965-2970.
  64. Badoual C, Hans S, Merillon N, Van Ryswick C, Ravel P, Benhamouda N, et al. PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. Cancer research. 2013;73(1):128-138.
  65. Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515(7528):568-571.
  66. Immunoscore Project 2015. Available from: (http://www.sitcancer.org/about-sitc/initiatives/immunoscore, Retrieved on 18 November 2015.
  67. Henson SM, Macaulay R, Riddell NE, Nunn CJ, Akbar AN. Blockade of PD-1 or p38 MAP kinase signaling enhances senescent human CD8(+) T-cell proliferation by distinct pathways. European journal of immunology. 2015;45(5):1441-1451.
  68. Spranger S, Koblish HK, Horton B, Scherle PA, Newton R, Gajewski TF. Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment. Journal for immunotherapy of cancer. 2014;2:3.
  69. Amancha PK, Hong JJ, Rogers K, Ansari AA, Villinger F. In vivo blockade of the programmed cell death-1 pathway using soluble recombinant PD-1-Fc enhances CD4+ and CD8+ T cell responses but has limited clinical benefit. Journal of immunology. 2013;191(12):6060-6070.
  70. Speiser DE, Utzschneider DT, Oberle SG, Munz C, Romero P, Zehn D. T cell differentiation in chronic infection and cancer: functional adaptation or exhaustion? Nature reviews Immunology. 2014;14(11):768-774.
  71. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. The New England journal of medicine. 2013;369(2):134-144.
  72. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. The New England journal of medicine. 2012;366(26):2455-2465.
  73. Sweeney CJ, Roth BJ, Kabbinavar FF, Vaughn DJ, Arning M, Curiel RE, et al. Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2006;24(21):3451-3457.
  74. Carvajal-Hausdorf DE, Schalper KA, Neumeister VM, Rimm DL. Quantitative measurement of cancer tissue biomarkers in the lab and in the clinic. Laboratory investigation; a journal of technical methods and pathology. 2015;95(4):385-396.
  75. Erdag G, Schaefer JT, Smolkin ME, Deacon DH, Shea SM, Dengel LT, et al. Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma. Cancer research. 2012;72(5):1070-1080.
  76. Spranger S, Spaapen RM, Zha Y, Williams J, Meng Y, Ha TT, et al. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Science translational medicine. 2013;5(200):200ra116.
  77. Carbognin L, Pilotto S, Milella M, Vaccaro V, Brunelli M, Calio A, et al. Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers. PloS one. 2015;10(6):e0130142.
  78. Barbee MS, Ogunniyi A, Horvat TZ, Dang TO. Current status and future directions of the immune checkpoint inhibitors ipilimumab, pembrolizumab, and nivolumab in oncology. The Annals of pharmacotherapy. 2015;49(8):907-937.